Physician profile
Clement C Chow
NPI 1265606461
$6,607.05
in general payments reported to CMS, 2019-2025
23 companies · $1,322 in 2025
The $1,322 reported for 2025 was more than what 83% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $315 · 2021: $353 · 2022: $663 · 2023: $1,593 · 2024: $1,620 · 2025: $1,322.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,174 · Long Term Medical Supply Or Device Loan: $360.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,173.69 |
| Long Term Medical Supply Or Device Loan | $360.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $1,321.59 | 2019-2025 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $909.95 | 2023-2025 | Izervay |
| Apellis Pharmaceuticals, INC. | $753.67 | 2022-2025 | Syfovre |
| Alcon Vision LLC | $482.00 | 2019-2023 | Ngenuity, Constellation |
| Regeneron Healthcare Solutions, INC. | $442.37 | 2019-2025 | Eylea Hd, Eylea |
| Carl Zeiss Meditec USA, INC. | $360.27 | 2023 | Lumera 700 |
| Mallinckrodt Hospital Products INC. | $321.80 | 2022-2025 | Acthar |
| Abbvie INC. | $319.78 | 2019-2025 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $280.87 | 2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $180.79 | 2019 | |
| Alimera Sciences, INC. | $167.36 | 2019-2023 | Yutiq |
| Ani Pharmaceuticals, INC. | $148.85 | 2024-2025 | Iluvien, Purified Cortrophin Gel, Yutiq |
| Eyepoint US, INC. | $146.69 | 2022-2024 | |
| Allergan, INC. | $130.27 | 2021 | |
| Akcea Therapeutics, INC. | $124.99 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $124.98 | 2024 | |
| Biogen, INC. | $116.23 | 2022-2023 | |
| Shire North American Group INC | $91.36 | 2019 | |
| Genentech, INC. | $51.39 | 2019 | |
| Harrow Eye, LLC | $45.66 | 2023-2024 | Iheezo |
| Optos, INC. | $38.62 | 2020 | |
| Amgen INC. | $29.92 | 2025 | Tepezza |
| Coherus Oncology, INC. | $17.64 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clement Chow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.